Novartis' third quarter to reflect $250 million-$300 million charge for Teva litigation

ZURICH, Switzerland Novartis’ third quarter report will show a $250 million-$300 million charge connected to patent litigation over its herpes drug Famvir.

Teva Pharmaceuticals recently launched a generic of the drug after a U.S. District Court in New Jersey denied Novartis’ request for a preliminary injunction. Teva though has stopped its sales of the drug on the order of the U.S. Federal Court of Appeals.

Novartis claims that it has worldwide rights for Famvir until 2015. The drug had sales of $166 million in the U.S. last year.